CLVR (Clever Leaves Holdings) Debt-to-Equity: 0.09 (As of Dec. 2023)

What is Clever Leaves Holdings Debt-to-Equity?

Clever Leaves Holdings CLVR 12 Debt-to-Equity is 0.09 as of Dec. 2023. GuruFocus rates CLVR with a GF Score™ of 12/100.

Clever Leaves Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.88 Mil. Clever Leaves Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.20 Mil. Clever Leaves Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $24.22 Mil. Clever Leaves Holdings's debt to equity for the quarter that ended in Dec. 2023 was 0.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Clever Leaves Holdings's Debt-to-Equity or its related term are showing as below:

CLVR's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

Clever Leaves Holdings (OTCPK:CLVR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Clever Leaves Holdings Debt-to-Equity Related Terms

Clever Leaves Holdings Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Clever Leaves Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clever Leaves Holdings Debt-to-Equity Chart

Clever Leaves Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.74

0.36

0.35

0.10

0.09

Clever Leaves Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												0.10	0.07	0.07	0.08	0.09

CLVR vs CNNC, CLSH, PRFX: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clever Leaves Holdings Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Clever Leaves Holdings's Debt-to-Equity falls into.

Save Embed

12GF Score

Clever Leaves Holdings Inc CLVR

Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Clever Leaves Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Clever Leaves Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.884	+	1.203)	/	24.217
	=	0.09

Clever Leaves Holdings's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.884	+	1.203)	/	24.217
	=	0.09

Frequently Asked Questions Learn more about Debt-to-Equity →

What does a Debt-to-Equity of 0.09 mean?

Clever Leaves Holdings (CLVR) has a Debt-to-Equity of 0.09 as of Dec. 2023. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Clever Leaves Holdings and its competitors.

Is Clever Leaves Holdings' Debt-to-Equity too high?

Clever Leaves Holdings' current Debt-to-Equity is 0.09. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Clever Leaves Holdings' value of 0.09 is 66.7% below this industry median. Overall, Clever Leaves Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does Clever Leaves Holdings' Debt-to-Equity compare to CNNC and CLSH?

Clever Leaves Holdings' Debt-to-Equity of 0.09 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.27. Clever Leaves Holdings' value of 0.09 is 66.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-Equity for a Drug Manufacturers company?

The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clever Leaves Holdings's current Debt-to-Equity of 0.09 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-Equity mean?

A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Clever Leaves Holdings and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clever Leaves Holdings's current Debt-to-Equity is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Clever Leaves Holdings stock overvalued right now?

Clever Leaves Holdings (CLVR) has a current Debt-to-Equity of 0.09. The current Debt-to-Equity is 0.09 and 66.7% below the Drug Manufacturers industry median of 0.27. Clever Leaves Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-Equity calculated?

Debt-to-Equity is calculated from a company's financial statements. For Clever Leaves Holdings (CLVR), the current Debt-to-Equity is 0.09 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clever Leaves Holdings Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies CNNC CLSH PRFX AGRX OWPC KOAN ABTI PLSH STEK INQD ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692

Address Bodega 19-B Parque Industrial Tibitoc P.H, Tocancipa, Cundinamarca, Bogota, COL

Website https://www.cleverleaves.com

Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments namely, the Cannabinoid segment which is comprised of the company's cultivation, extraction, and commercialization of cannabinoid products; and the Non-Cannabinoid operating segment which generates maximum revenue and is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.

12GF Score

Get the complete analysis for CLVR

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View CLVR Analysis

See Debt-to-Equity data for all stocks →